The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Beam Therapeutics Inc. COM 07373V105 304,095 2,362,635 SH   DFND 1 2,362,635 0 0
VIR BIOTECHNOLOGY INC COM 92764N102 3,534 74,743 SH   DFND 1 74,743 0 0
LYELL IMMUNOPHARMA INC COM 55083R104 330,147 20,329,235 SH   DFND 1 20,329,235 0 0
RELX PLC SPONSORED ADR 759530108 380,096 43,539,020 SH   DFND 1 43,539,020 0 0